News | News By Subject | News by Disease News By Date | Search News

Schizophrenia News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Minerva Neurosciences (NERV)'s Stock More than Tripled on Positive Phase II Schizophrenia Drug Data     5/27/2016
FDA Spurns Otsuka Pharma, Proteus Digital Health's Drug/Device Combo     4/27/2016
Arena (ARNA) Scores a $262 Million Schizophrenia Deal with Boehringer Ingelheim     1/13/2016
Neurocrine Biosciences (NBIX)'s NBI-98854 Hits Primary Enpoint in Phase III Study     10/9/2015
FDA Green Lights Alkermes (ALKS)' Schizophrenia Treatment Aristada     10/7/2015
FDA Approves Allergan (AGN) and Gedeon Richter (RIG2.F)'s Antipsychotic Vraylar     9/18/2015
Intra-Cellular Therapies Surges as Schizophrenia Drug Met Primary Endpoint in Phase III     9/17/2015
FORUM Pharma Halts Clinical Trials for Alzheimer’s and Schizophrenia Drug     9/17/2015
GW Pharma (GWPH) Surges on Positive Phase II Cannabis-Based Drug Study for Schizophrenia and Some Rare Diseases     9/16/2015
EXCLUSIVE: Moleculera Labs Will Add Close to A Dozen As It Doles Out $300K Grant     7/8/2015
In Hearings, University of Minnesota Admits Problems in Solvay Pharmaceuticals, Inc.’s Schizophrenia Drug     5/11/2015
Deaths Review of Eli Lilly (LLY)'s Antipsychotic Zyprexa Relprevv "Inconclusive"     3/25/2015
2015 Could Be Blockbuster Year for Alkermes plc (ALKS), Says Citi     12/17/2014
Pfizer (PFE)'s Antipsychotic Geodon Could Cause Fatal Skin Reaction: FDA     12/15/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014

News from Around the Web
Spotlight Hits This Little-Known Generic Biotech That Raised Price of Schizophrenia Drug by 1,650%     10/7/2016
How Artificial Intelligence Could Help Diagnose Mental Disorders, NeuroLex Diagnostics Reveals     9/2/2016
For Young People With Schizophrenia, Physical And Mental Exercises Offer Hope, UCLA Study     4/6/2016
Low Brain Levels of Vitamin B12 in Schizophrenics and Autistic Patients, Nova Southeastern University Researchers Reveal     1/25/2016
High Fat/Low Carb Diet Could Combat Schizophrenia, James Cook University Study     12/18/2015
Brain Scans Suggest Schizophrenia Is Not One Disease, Washington University in St. Louis Study Reveals     10/16/2015
Cannabis May Cause Schizophrenia, University of Calgary Researcher Warns     9/24/2015
Brain Scans May Help Schizophrenia Treatment, Zucker Hillside Hospital Study     9/17/2015
Retinal Changes Offer Clues About Brain Pathology Of Schizophrenia, Rutgers University Study     9/11/2015
Microbiomes Associated With Schizophrenia ID'd, George Washington University Study     8/26/2015
Can Fish Oil Slow Down Schizophrenia? University of Melbourne Study     8/13/2015
A Little Jolt Helps The Brain Get Back On Track, Vanderbilt University Study     7/9/2015
Presidential Candidate Mike Huckabee Uses Schizophrenia As A Slur, Gets It Wrong     7/7/2015
Does Creativity Share Genetic Roots With Schizophrenia? Maybe, King's College London Study     6/9/2015
Republican Claims Pot Enhances Psychosis And Schizophrenia     5/6/2015

Press Releases
Sunovion Initiates SEP-363856 Phase II Program For Patients With Schizophrenia Or Parkinson’s Disease Psychosis     12/2/2016
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia     11/15/2016
Acadia (ACAD) Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia     11/3/2016
Sunovion Announces Positive Clinical Study Results For Latuda (Lurasidone HCL) In Adolescents With Schizophrenia     10/27/2016
Alkermes (ALKS) Announces Initiation Of Clinical Study Evaluating Metabolic Profile Of ALKS 3831 For Treatment Of Schizophrenia     10/3/2016
Intra-Cellular Therapies's Future Up in the Air as Stock Plunges After Schizophrenia Study Fails     9/29/2016
Otsuka Pharmaceutical Development & Commercialization, Inc. Release: FDA Approves Labeling Update Of REXULTI (brexpiprazole) For Maintenance Treatment Of Schizophrenia     9/26/2016
Pear Therapeutics Release: The Largest And Longest Study Of Patients With Schizophrenia Interacting With Digital Therapeutics Results Released     8/25/2016
Sunovion Pharmaceuticals Inc. Announces Publication Of Data Evaluating Dose Escalation Of Latuda (Lurasidone HCL) In The Treatment Of Schizophrenia     8/8/2016
Alkermes (ALKS) Submits Supplemental New Drug Application To FDA For Two-Month Dosing Option Of ARISTADA For Treatment Of Schizophrenia     8/8/2016
Autifony Therapeutics Successfully Completes Phase I Study Of AUT00206, A First-In-Class Kv3 Modulator For Schizophrenia     8/1/2016
Health Canada Approves Janssen's Invega Trinza for Schizophrenia     6/27/2016
Vanda Pharmaceuticals, Inc. (VNDA) Release: FDA Grants Fanapt Three Years Of Marketing Exclusivity for Labeling Changes Relating To Maintenance Treatment Of Schizophrenia     6/16/2016
Janssen-Cilag International NV (JNJ) Release: European Commission (EC) Approves TREVICTA (Paliperidone Palmitate A 3-Monthly Injection), For Maintenance Treatment Of Schizophrenia     5/31/2016
Vanda Pharmaceuticals, Inc. (VNDA) Announces FDA Approval Of The Fanapt Supplemental New Drug Application For Maintenance Treatment Of Schizophrenia In Adults     5/27/2016

//-->